<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582656</url>
  </required_header>
  <id_info>
    <org_study_id>VIOLETTE</org_study_id>
    <secondary_id>2019-A00803-54</secondary_id>
    <nct_id>NCT04582656</nct_id>
  </id_info>
  <brief_title>Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer</brief_title>
  <acronym>VIOLETTE</acronym>
  <official_title>Prospective Multicenter Trial Assessing the Efficacy of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Koelis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Koelis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective, European, single-arm, open-label, 12-month follow-up clinical&#xD;
      trial. The purpose of this study is to evaluate the efficacy of a 3D cartography-based&#xD;
      targeted microwave ablation for the treatment of the index lesion in patients with&#xD;
      intermediate risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      European and American guidelines recommend several therapeutic alternatives: radical surgical&#xD;
      treatment, external beam radiotherapy or brachytherapy. However, whole-gland treatment&#xD;
      induces significant morbidity and burden on quality of life. Targeted treatments of the index&#xD;
      tumor are currently under investigation to decrease morbidity while proposing active&#xD;
      treatment.&#xD;
&#xD;
      The purpose of this study is to assess the efficacy of a novel ablation treatment using&#xD;
      microwaves, delivered transrectally or transperineally under real-time guidance with&#xD;
      MRI-transrectal ultrasound image registration. The index tumor will be detected with prostate&#xD;
      MRI and characterized with targeted biopsies using Organ Based Tracking (OBT) fusion with the&#xD;
      TRINITY system (KOELIS, Meylan, France). The same system will be used to identify the index&#xD;
      lesion and guide the targeted microwave ablation performed with the TATO3 device (Biomedical&#xD;
      Srl, Florence, Italy).&#xD;
&#xD;
      All patients will undergo biopsy at 12 months of follow-up. A biopsy session will also be&#xD;
      performed at 6 months, but only for patients with imaging results suspicious for cancer&#xD;
      within the ablated area on the mpMRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, single-arm, open-label, 12-month follow-up clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with no evidence of cancer on targeted biopsy</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of patients with no evidence of cancer on targeted biopsy at 12 months, defined by a minimum of 2 targeted core biopsies taken from the index tumor site treated with microwave ablation for focal treatment of intermediate risk prostate cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of radical salvage treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients undergoing radical salvage treatment of the index lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radical salvage treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Time to radical salvage treatment of the index lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with any cancer in the untreated area</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with any cancer in the untreated area, determined by a minimum 12 cores systematic biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients undergoing treatment for cancer in the untreated area</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients undergoing treatment for cancer in the untreated area and time to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS questionnaire</measure>
    <time_frame>7 days and 1, 6 and 12 months</time_frame>
    <description>Changes in patients' reported outcome measures (PROMs) for urinary symptoms using IPSS score compared to baseline, score ranging from 0 to 35 (the higher the worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF-5 questionnaire</measure>
    <time_frame>7 days and 1, 6 and 12 months</time_frame>
    <description>Changes in patients' reported outcome measures (PROMs) for erectile function using IIEF-5 score compared to baseline, score ranging from 5 to 25 (the lower the worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSHQ-EjD-SF questionnaire</measure>
    <time_frame>7 days and 1, 6 and 12 months</time_frame>
    <description>Changes in patients' reported outcome measures (PROMs) for ejaculatory function and bother using MSHQ-EjD-SF score compared to baseline, score ranging from 1 to 15 (the lower the worse) for ejaculatory function and from 0 to 5 for bother/satisfaction (the higher the worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine flow</measure>
    <time_frame>7 days and 1, 6 and 12 months</time_frame>
    <description>Change in urine flow, using a uroflowmeter compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Number and severity of device and procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient post-operative pain level</measure>
    <time_frame>Treatment day-evaluated between 2 and 4 hours after the procedure</time_frame>
    <description>Average patient post-operative pain level reported on a pain numeric rating scale, with a range from 0 (no pain) to 10 (worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>Patient satisfaction with the microwave ablation procedure as determined by questionnaire (no score assigned)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of the procedure</measure>
    <time_frame>Day 1</time_frame>
    <description>Ease of the procedure measured with a score chosen by the operator (1: easy, 2: moderate, 3: difficult)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the procedure and associated variables</measure>
    <time_frame>Day 1</time_frame>
    <description>Duration of the procedure and associated variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>Change in PSA measurement compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Nadir</measure>
    <time_frame>12 months</time_frame>
    <description>Time to PSA Nadir after treatment of the index lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate volume</measure>
    <time_frame>7 days and 6 and 12 months</time_frame>
    <description>Change in volume of the prostate on the mpMRI compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient motivation</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of patient motivation to undergo targeted microwave ablation for treatment of the index lesion, as assessed by patient questionnaire (no score assigned)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Targeted microwave ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted microwave transrectal or transperineal ablation of the prostatic index tumor using MRI-transrectal image registration and OBT fusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Targeted microwave ablation</intervention_name>
    <description>Targeted ablation of the index tumor with microwaves, by using either a transperineal or a transrectal approach</description>
    <arm_group_label>Targeted microwave ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged from 45 to 76 years old&#xD;
&#xD;
          -  Life expectancy &gt;10 years at the inclusion time&#xD;
&#xD;
          -  Patient diagnosed with an intermediate-risk prostate cancer, defined by:&#xD;
&#xD;
               -  A T1c or T2a clinical stage&#xD;
&#xD;
               -  A unique cancer focus of Gleason (3+4) (Grade Group 2)&#xD;
&#xD;
               -  A PSA level &lt;20 ng/mL&#xD;
&#xD;
          -  Cancer focus identified on a multiparametric MRI of the prostate no more than 3 months&#xD;
             before inclusion&#xD;
&#xD;
          -  Confirmation of the suspicion of cancer identified on the MRI with transrectal or&#xD;
             transperineal targeted and systematic biopsies performed with the KOELIS TRINITY&#xD;
             system (no more than 3 months before inclusion)&#xD;
&#xD;
          -  Patient suitable for IV sedation or general anesthesia and focal microwave ablation&#xD;
&#xD;
          -  No debilitating medical or psychiatric illness that would preclude giving informed&#xD;
             consent or receiving optimal treatment and follow-up&#xD;
&#xD;
          -  Known coagulopathy or bleeding disorders are controlled&#xD;
&#xD;
          -  Free, informed and written consent, dated and signed before the enrollment and before&#xD;
             any exam required by the trial&#xD;
&#xD;
          -  Patient affiliated to social security regimen or beneficiary of such regimen for local&#xD;
             regions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past medical history of prostate surgery&#xD;
&#xD;
          -  Past medical history of radiotherapy or pelvic trauma&#xD;
&#xD;
          -  Past medical history of acute prostatitis&#xD;
&#xD;
          -  Presently taking hormonal manipulation or androgen supplements.&#xD;
&#xD;
          -  Past medical history of cancer in the 5 previous years, excluding a non-metastatic&#xD;
             basal cell carcinoma of the skin&#xD;
&#xD;
          -  Severe BPH-related urinary tract symptoms, defined by an IPSS score &gt;18&#xD;
&#xD;
          -  Serious medical illness, including any of the following: uncontrolled congestive heart&#xD;
             failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6&#xD;
             months prior to the screening visit&#xD;
&#xD;
          -  Contraindications for MRI exam&#xD;
&#xD;
          -  Extracapsular cancer extension or seminal vesicles or pelvic lymph node invasion&#xD;
             suspected on prostate MRI&#xD;
&#xD;
          -  Presence of two or more clinically significant cancer foci in the inclusion biopsy&#xD;
             exam&#xD;
&#xD;
          -  Presence of a clinically significant cancer with a Gleason score ≥8 (Grade Group ≥4)&#xD;
&#xD;
          -  Tumor largest axis &gt;12 mm on the prostate MRI&#xD;
&#xD;
          -  Distance between the cancer focus and the apex &lt;10 mm on the prostate MRI&#xD;
&#xD;
          -  Distance between the cancer focus and the rectum &lt;5 mm on the prostate MRI&#xD;
&#xD;
          -  Patient already participating in an interventional clinical trial&#xD;
&#xD;
          -  Patient protected by law&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland VAN VELTHOVEN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Uro Science &amp; Consulting</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damien FONTANELLI, MSc</last_name>
    <phone>+33 4 58 17 68 10</phone>
    <email>fontanelli@koelis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre PELTIER, MD</last_name>
      <phone>+32 (0) 2 541 31 71</phone>
      <email>alexandre.peltier@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Alexandre PELTIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck BLADOU, MD</last_name>
      <phone>+ 33 (0) 5 57 82 28 00</phone>
      <email>franck.bladou@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Franck BLADOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Hospital of Paris</name>
      <address>
        <city>Neuilly-sur-Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurel MESSAS, MD</last_name>
      <phone>+33 (0) 1 46 41 25 25</phone>
      <email>aurel.messas@ahparis.org</email>
    </contact>
    <investigator>
      <last_name>Aurel MESSAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpêtrière (Assistance Publique - Hôpitaux de Paris)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MOZER, MD</last_name>
      <phone>+33 (0) 1 42 17 71 50</phone>
      <email>pierre.mozer@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre MOZER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin (Assistance Publique - Hôpitaux de Paris)</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas BARRY DELONGCHAMPS, MD</last_name>
      <phone>+33 (0) 1 58 41 27 52</phone>
      <email>nicolas.barry-delongchamps@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas BARRY DELONGCHAMPS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologie Nantes Clinique &amp; Institut d'Urologie - Site Atlantis</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric POTIRON, MD</last_name>
      <phone>+33 (0) 2 28 03 06 09</phone>
      <email>ep@cliniqueuro.com</email>
    </contact>
    <investigator>
      <last_name>Eric POTIRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard MALAVAUD, MD</last_name>
      <phone>+33 (0) 5 31 15 60 16</phone>
      <email>malavaud.bernard@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard MALAVAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Prostate</keyword>
  <keyword>Targeted treatment</keyword>
  <keyword>Microwave</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

